Grupo Ferrer Internacional S.A. Successfully Completes an Absorption, Tolerability and Safety Study in Juveniles as Young as Two Months of Age for Novel Antibacterial Compound Ozenoxacin
10/5/2012 11:00:15 AM
More...
|
Ferrer Submits IND for Arasertaconazole Nitrate, a Safe, Fast-Acting Topical Antifungal in Development for Vulvovaginal Candidiasis
8/8/2012 10:48:09 AM
More...
|
Alexza Pharmaceuticals, Inc. (ALXA) and Grupo Ferrer Internacional S.A. Amend Adasuve(TM) Partnership
3/8/2012 10:14:49 AM
More...
|
Alexza Pharmaceuticals, Inc. (ALXA) and Grupo Ferrer Internacional S.A. Establish $10 Million Partnership for the Commercialization of Adasuve(TM) (Staccato(R) Loxapine) in Europe and Latin America
10/6/2011 7:08:59 AM
More...
|
Vasogen (VSGN) and Grupo Ferrer Internacional S.A. Announce Initial Roll-out of Celacade
12/17/2007 7:58:49 AM
More...
|
Vasogen (VSGN) and Grupo Ferrer Internacional S.A. Form Collaboration to Commercialize Celacade(TM) in the European Union
4/18/2007 10:34:36 AM
More...
|
NicOx SA (NCOX.F) And Grupo Ferrer Internacional S.A. Select Candidate For Development In Dermatology Collaboration
5/16/2006 10:36:17 AM
More...
|
Barrier Therapeutics, Inc. (BTRX) Establishes European Commercialization Agreement Covering Four Products
10/19/2005 5:12:03 PM
More...
|
Indevus Pharmaceuticals, Inc. (IDEV) Announces Licensing Agreement Between Grupo Ferrer And IVAX Corporation (IVX) Related To Citicoline
10/19/2005 5:11:55 PM
More...
|
IVAX Corporation (IVX) And Grupo Ferrer Internacional S.A. To Collaborate On Late-Stage Drug For Acute Stroke
10/19/2005 5:11:54 PM
More...
|